https://scholars.lib.ntu.edu.tw/handle/123456789/496610
標題: | Reversine, a 2,6-disubstituted purine, as an anti-cancer agent in differentiated and undifferentiated thyroid cancer cells | 作者: | Hua S.-C. TIEN-CHUN CHANG Chen H.-R. Lu C.-H. Liu Y.-W. Chen S.-H. Yu H.-I. Chang Y.-P. Lee Y.-R. |
公開日期: | 2012 | 卷: | 29 | 期: | 7 | 起(迄)頁: | 1990-2005 | 來源出版物: | Pharmaceutical Research | 摘要: | Purpose: A novel and effective treatment is urgently needed to deal with the current treatment dilemma in incurable differentiated thyroid cancer (DTC), poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC). Reversine, a small synthetic purine analogue (2,6-disubstituted purine), has been shown to be effective in tumor suppression. Methods: We performed in vitro evaluation of anti-tumor effects of reversine on proliferation, cell cycle, and apoptosis in human PDTC, ATC, and follicular thyroid cancer cell lines, respectively. Results: Treatment of these three lines with reversine inhibited proliferation in a time- and dose-dependent manner. G2/M accumulation was demonstrated in cell cycle analysis. Reversine induced apoptosis in PDTC cells with caspase-3 and caspase-8 activation, but not caspase-9. Use of a pan-caspase inhibitor before treatment with reversine attenuated cell death. Reversine also showed in vivo growth inhibitory effects on ATC cells in a xenograft nude mice model. Conclusions: Data demonstrated that reversine is effective in inhibiting the growth of thyroid cancer cells by cell cycle arrest or apoptosis, especially with the more aggressive ATC and PDTC. Apoptosis was induced by the mitochondria-independent pathway. Reversine is therefore worthy of further investigation in clinical therapeutics. ? 2012 Springer Science+Business Media, LLC. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84862635118&doi=10.1007%2fs11095-012-0727-3&partnerID=40&md5=91c9ec843c8c26ff2724b74ec04e139f https://scholars.lib.ntu.edu.tw/handle/123456789/496610 |
ISSN: | 0724-8741 | DOI: | 10.1007/s11095-012-0727-3 | SDG/關鍵字: | antineoplastic agent; caspase 3; caspase 8; caspase 9; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase; purine derivative; reversine; unclassified drug; animal experiment; animal model; antineoplastic activity; apoptosis; article; cancer cell; cancer inhibition; cell cycle; cell cycle arrest; cell differentiation; cell proliferation; controlled study; differentiated thyroid cancer; dose time effect relation; drug efficacy; drug inhibition; drug screening; enzyme activation; G2 phase cell cycle checkpoint; human; human cell; in vitro study; M phase cell cycle checkpoint; male; mouse; nonhuman; poorly differentiated thyroid cancer; priority journal; thyroid follicular carcinoma; tumor xenograft; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 8; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Purines; Thyroid Gland; Thyroid Neoplasms |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。